Skip to content

Integrated Discovery and Development of Innovative TB Diagnostics

Integrated Discovery and Development of Innovative TB Diagnostics

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06624501
Acronym
(CETR)
Enrollment
1450
Registered
2024-10-03
Start date
2015-05-01
Completion date
2020-02-28
Last updated
2024-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis, Pulmonary

Keywords

pediatric, diagnostic, cell-free DNA, molecular, tuberculosis

Brief summary

The long term goal of this project is to provide information critical to the development and use of a low-cost, point-of-care, rapid, simple, and highly accurate diagnostic tool that can help clinicians make a microbiological diagnosis in children who present with signs and symptoms suggestive of TB. Specific aim 1: To identify the types of patient samples from which to best detect Mtb DNA in children with TB. We propose to obtain serial samples of sputum, blood, stool, and gastric and nasopharyngeal secretions from children with symptomatic TB and to use molecular methods to characterize the distribution of Mtb in these samples. The results of this study will allow us to identify the most promising sampling strategies for diagnosis of TB in children so that optimization of these easily-accessible samples for detection of Mtb nucleic acids can be addressed. Specific aim 2: To determine whether cell free Mtb DNA can be detected in plasma and urine samples of children and adults with TB and to describe the host-related factors that alter the sensitivity of this assay. We propose to test serial urine and plasma samples for Mtb DNA fragments in two groups: (1) children with symptoms of TB and (2) adults with TB. Here, we will optimize sample volume sizes and of state-of-the-art sequencing tools to improve DNA recovery and detection. This study will help identify optimal samples and strategies for the non-invasive diagnosis of Mtb using urine. Secondary aim: To create a bank of archived specimens for (1) optimization of Mtb DNA purification, extraction, and (2) use in future pediatric TB diagnostic research.

Interventions

Sponsors

Harvard University Faculty of Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

for aim 1: Children must meet all of the following criteria at the time of enrollment to participate: * Age \< 15 years; * Presents to a participating health center; * Meets the Criteria for Enrollment of Children Into TB Diagnostic Evaluation Studies * Has a history of contact with an adult with TB disease; and * A guardian provides informed consent for minor to participate and, if age 8 to 14 years, the minor also provides assent. Inclusion criteria for aim 2: Inclusion criteria for children who participate in Aim 2 will be the same as for those for Aim 1. Adults who participate in Aim 2 must meet all of the following criteria at the time of enrollment to participate. * Age ≥ 18 years; * Presents to a participating health center; * Is diagnosed with incident pulmonary TB; * Has sputum smear microscopy results; * Has not yet initiated tuberculosis treatment; and * Is willing to receive a rapid HIV test.

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity for detection of Mtb, by sample typeBaselineFor each type of biologic specimen, the proportion of samples in which Mtb could be isolated by DNA detection methods (sensitivity) relative to the standard of care (a combination of sputum smear, sputum culture, signs and symptoms).

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026